Phase I dose escalation study of oral administration of Pan-Histone Deacetylase (HDAC) inhibitor S 78454 given in combination with a fixed dose infusion of cisplatin in patients with advanced non-keratinising nasopharyngeal carcinoma.
Phase of Trial: Phase I
Latest Information Update: 03 Apr 2018
At a glance
- Drugs Abexinostat (Primary) ; Cisplatin
- Indications Nasopharyngeal cancer
- Focus Adverse reactions
- 14 Jun 2012 New trial record